AKTS
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States. It operates through two segments, Foundry Fabrication Services and RF Filters. The Foundry Fabrication Services segment provides engineering review services; and semiconductor wafer-manufacturing and microelectromechanical systems foundry services. The RF Filters segment consists of amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense applications. The company was incorporated in 2013 and is headquartered in Huntersville, North Carolina.
Aktis Oncology, Inc. (AKTS) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | C+ (2.5) | C (2.5) | C (2.3) | D+ (1.8) | C+ (2.6) | C (2.4) |
| 2026-11-10 | C (2.4) | C (2.5) | D- (0.8) | C (2.2) | C+ (2.6) | C- (2.1) |
| 2026-11-03 | C (2.5) | C (2.4) | D- (0.8) | C- (2.1) | C+ (2.7) | C- (2.1) |
| 2026-10-27 | C (2.5) | C (2.5) | D- (0.8) | C- (2.0) | C+ (2.6) | C- (2.1) |
| 2026-10-20 | C+ (2.5) | C (2.5) | D- (0.8) | C- (2.1) | C+ (2.6) | C- (2.1) |